Compare Gartner Inc (IT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Gartner (IT) trades at $195.09, up 5.02% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with support at $185 and resistance at $188. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though 2025 net income declined to $729M from 2024's $1.3B. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium in October.

Outlook remains positive with analyst consensus at Buy (28%) and $174.63 price target, though current price exceeds target. Key opportunities include strong ROE (113.58%) and AI-driven consulting demand. Risks include negative cash flow trends (-$211M in 2025) and potential fiduciary investigation noted in recent filings. Institutional sentiment appears mixed with 56% Hold ratings.

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.